Complex generics, proprietary products to drive growth: DRL

Dr Reddy’s Laboratories had posted a consolidated net income from sales and services of Rs 15,470.8 crore for 2015-16 fiscal. (Source: Express Archive)
Dr Reddy’s Laboratories (DRL) expects complex generics, proprietary products, including creation of branded generics platform in the US, to be the main drivers of its growth going forward.
“Our growth, going forward, will be driven by the attractive pipeline of complex generics as well as our new proprietary products,” Dr